title: S 16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin) is a potent and long-acting bradykinin B2 receptor antagonist, in vitro and in vivo.
abstract: The in vitro and in vivo effects of S 16118 [p-guanidobenzoyl-[Hyp3, Thi5,D-Tic7,Oic8]bradykinin (BK)], a new BK receptor antagonist, were studied. S 16118 inhibited the contraction produced by BK in the rabbit jugular vein, but was ineffective in the rabbit aorta, indicating the BK B2 receptor specificity of the compound. In isolated organs from various species including humans, S 16118 was a potent antagonist (Ki, pA2 or pKB value from 9.58-7.37). The effect of S 16118 was specific as it did not show any affinity for a number of other receptors or channels and did not possess residual agonistic properties in most of the tissues studied. Furthermore, S 16118 is a poor secretagogue agent either in the rat or human mast cells and is resistant to degradation with an in vitro half-life in blood from different species, including humans, of more than 24 hr. In vivo, in the rabbit, i.v. injection of S 16118 inhibited the hypotension induced by BK up to 4 hr after administration. In the guinea pig, it was also effective in inhibiting the bronchoconstriction induced by BK, although when administered i.v. it had a shorter duration than in the rabbit. However, in the same species, when aerosolized, S 16118 was effective and long-acting against BK-induced bronchoconstriction. Changes in permeability induced by BK injection in the guinea pig trachea and bronchus, and by BK superfusion in the hamster cheek pouch, were abolished by i.v. pretreatment with S 16118.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division de Pneumologie, Institut de Recherches Servier, Suresnes, France.
authors.forename: M
authors.initials: M
authors.lastname: Félétou
authors.forename: P
authors.initials: P
authors.lastname: Robineau
authors.forename: M
authors.initials: M
authors.lastname: Lonchampt
authors.forename: E
authors.initials: E
authors.lastname: Bonnardel
authors.forename: C
authors.initials: C
authors.lastname: Thurieau
authors.forename: J L
authors.initials: JL
authors.lastname: Fauchère
authors.forename: P
authors.initials: P
authors.lastname: Widdowson
authors.forename: J P
authors.initials: JP
authors.lastname: Mahieu
authors.forename: B
authors.initials: B
authors.lastname: Serkiz
authors.forename: J P
authors.initials: JP
authors.lastname: Volland
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D016084:Bronchoconstriction / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D015550:Cell Degranulation / Q000187:drug effects; D002478:Cells, Cultured; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D043782:Receptor, Bradykinin B2
chemical_list: D000959:Antihypertensive Agents; D065168:Bradykinin Receptor Antagonists; D043782:Receptor, Bradykinin B2; C094195:S 16118; D001920:Bradykinin